DTech Liquidating

DTech Liquidating News

News

0

Ticker

DMTKQ

ISIN

US24984K1051

Chiffre d'affaires Résultat net P/E P/S EBIT Dividende Achats de membres du conseil Actions Capitalisation boursière Endettement Passifs Capitaux propres AAQS Effectifs ROE ROA ROCE News Documents

Actualités Eulerpool DTech Liquidating

Actualités de l'action DTech Liquidating

DTech Liquidating est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant DTech Liquidating.

Communiqués de presse relatifs à l'action DTech Liquidating

DTech Liquidating publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.

DTech Liquidating News 2026

Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action DTech Liquidating (DMTKQ, ISIN : US24984K1051). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez DTech Liquidating.

DTech Liquidating Action

DTech Liquidating DTech Liquidating Inc, trading under the ticker DMTKQ with ISIN US24984K1051, is a U.S.-based company headquartered in San Diego. It operates within the Health Care sector, specifically in the Biotechnology industry. The company has 278 employees and completed its IPO on June 20, 2017. DTech Liquidating Inc is focused on the development and sale of products for the diagnosis and treatment of skin diseases. Its technology involves non-invasive genomics tests designed to aid in the diagnosis and management of skin cancer, inflammatory skin diseases, and aging-related skin conditions. The company utilizes a method that detects genomic markers associated with melanoma through non-invasive skin sample collection, aiming to identify higher-risk lesions at early stages to rule out melanoma. The DermTech Melanoma Test, also known as the DMT or Pigmented Lesion Assay (PLA), is marketed for the clinical assessment of pigmented skin lesions that may indicate melanoma. The company's products are intended to address unmet needs in the diagnostic process for pigmented skin lesions, commonly referred to as moles. DTech Liquidating Inc's operations are centered around providing innovative solutions for skin disease diagnosis and management, leveraging non-invasive genomic analysis techniques.